Harold Elliot Varmus, M.D.
Affiliations: | Medical Education | UC Berkeley, NIH, Sloan Kettering |
Area:
Medical OncologyWebsite:
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1989/varmus-bio.htmlGoogle:
"Harold Varmus"Bio:
The Nobel Prize in Physiology or Medicine 1989 was awarded jointly to J. Michael Bishop and Harold E. Varmus "for their discovery of the cellular origin of retroviral oncogenes"
Cross-listing: Cell Biology Tree - GenetiTree
Parents
Sign in to add mentor| J. Michael Bishop | post-doc | 1970-1972 | UC Berkeley / UCSF (FlyTree) | |
| Ira Pastan | research scientist | 1968-1970 | NIH (Neurotree) | |
| Mike Fried | research scientist | 1978-1979 | Imperial Cancer Research Fund (Cell Biology Tree) | |
| (sabbatical) | ||||
Children
Sign in to add trainee| Tyler Jacks | grad student | UCSF (Cell Biology Tree) | |
| Peter Pryciak | grad student | (Neurotree) | |
| Gregory S. Payne | grad student | 1982 | UCSF (Cell Biology Tree) |
| Joshua M. Kaplan | grad student | 1986-1990 | UCSF (Neurotree) |
| Kari Alitalo | post-doc | UCSF (Cell Biology Tree) | |
| Donald E. Ganem | post-doc | UCSF (Cell Biology Tree) | |
| Roeland Nusse | post-doc | UCSF (Chemistry Tree) | |
| Sandra Orsulic | post-doc | ||
| Rolf Sprengel | post-doc | (Neurotree) | |
| John A. T. Young | post-doc | UCSF (ID Tree) | |
| Chi Van Dang | post-doc | 1978-1982 | UCSF |
| Patrick O. Brown | post-doc | 1985-1988 | UCSF (FlyTree) |
| Titia de Lange | post-doc | 1985-1990 | UC Berkeley (Telomere and Telomerase Tree) |
| Paul F. Bates | post-doc | 1985-1992 | UCSF (Cell Biology Tree) |
| Pamela L. Schwartzberg | post-doc | 1995-1999 | NIH (Chemistry Tree) |
| Eric Holland | post-doc | 1996-1999 | NIH |
| Bart O Williams | post-doc | 1996-1999 | National Cancer Institue-NIH (Neurotree) |
| Yi Li | post-doc | 1997-2002 | NIH, Sloan Kettering |
| Katerina A. Politi | post-doc | 2003-2009 | Memorial Sloan-Kettering Cancer Center (Cell Biology Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stein BD, Ferrarone JR, Gardner EE, et al. (2023) LKB1-dependent regulation of TPI1 creates a divergent metabolic liability between human and mouse lung adenocarcinoma. Cancer Discovery |
| Froeling FE, Robine N, Hubert B, et al. (2020) Abstract 5128: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York Cancer Research. 79: 5128-5128 |
| Chen HJ, Poran A, Unni AM, et al. (2019) Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells. The Journal of Experimental Medicine |
| Unni AM, Harbourne B, Oh MH, et al. (2018) Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. Elife. 7 |
| Fei DL, Zhen T, Durham B, et al. (2018) Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene . Proceedings of the National Academy of Sciences of the United States of America |
| Fan PD, Narzisi G, Jayaprakash AD, et al. (2018) amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America |
| Fan P, Narzisi G, Jayaprakash A, et al. (2017) YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. Journal of Clinical Oncology. 35: 9043-9043 |
| De Silva T, Martinez V, Thu K, et al. (2017) P1.02-073 Characterizing the Genomes of Lung Adenocarcinomas from Never Smokers Reveals SHPRH as a Novel Candidate Tumor Suppressor Gene Journal of Thoracic Oncology. 12: S532-S533 |
| Fei DL, Motowski H, Chatrikhi R, et al. (2016) Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival. Plos Genetics. 12: e1006384 |
| McFadden DG, Politi K, Bhutkar A, et al. (2016) Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America |